CAMP4 Therapeutics closes $100m round to advance lead regRNA programmes
Biotechnology company CAMP4 Therapeutics has closed a $100m Series B round to progress its lead regRNA programmes and speed up the expansion of its regRNA Actuating Platform.
Fast, Ad-Free News Updates
Stay updated with breaking news from James Boylan. Real-time updates on events, politics, business and more.